biostudies-literatureUrbanska KNCI NIH HHS1130-7https://www.ebi.ac.uk/biostudies/studies/S-EPMC4596767biostudies-literatureUnknown3(10)Adoptive transfer of T cells engineered to express chimeric immunoreceptors is an effective strategy to treat hematologic cancers; however, the use of this type of therapy for solid cancers, such as ovarian cancer, remains challenging because a safe and effective immunotherapeutic target has not yet been identified. Here, we constructed and evaluated a novel redirected T-cell-based immunotherapy targeting human follicle-stimulating hormone receptor (FSHR), a highly conserved molecule in vertebrate animals with expression limited to gonadal tissues, ovarian cancer, and cancer-associated vasculature. Receptor ligand-based anti-FSHR immunoreceptors were constructed that contained small binding fragments from the ligand for FSHR, FSH, fused to T-cell transmembrane and T-cell signaling domains.Cancer immunology researchFollicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.PMC4596767R01 CA168900R01-CA168900Stashwick CUrbanska KPoussin MPowell DJfalseFollicle-Stimulating Hormone Receptor as a Target in the Redirected T-cell Therapy for Cancer.Adoptive transfer of T cells engineered to express chimeric immunoreceptors is an effective strategy to treat hematologic cancers; however, the use of this type of therapy for solid cancers, such as ovarian cancer, remains challenging because a safe and effective immunotherapeutic target has not yet been identified. Here, we constructed and evaluated a novel redirected T-cell-based immunotherapy targeting human follicle-stimulating hormone receptor (FSHR), a highly conserved molecule in vertebrate animals with expression limited to gonadal tissues, ovarian cancer, and cancer-associated vasculature. Receptor ligand-based anti-FSHR immunoreceptors were constructed that contained small binding fragments from the ligand for FSHR, FSH, fused to T-cell transmembrane and T-cell signaling domains.2015-01-01T00:00:00Z2015 Oct2025-04-19T14:59:14.656Z2019-03-27T01:59:40ZS-EPMC45967672611292310.1158/2326-6066.cir-15-004710.1158/2326-6066.CIR-15-0047